CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

pegylated arginine deiminase

Recombinant proteinexperimental

Clinical trial activity

51 trials · 31 clinical orgs · 0 marketing orgs

Phase 1
28
Phase 2
31
Phase 3
7
Phase 4
0

Earliest trial started Sep 1, 2001 (NCT00029900)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • adi-peg
  • adi-peg
  • adi peg20
  • adi-peg20
  • adi-peg20
  • adi-ss
  • aeb1102
  • arginase 1 peg5000
  • peg 20
  • pegargiminase
  • peg-bct-100
  • pegylated arginine deiminase
  • pegylated arginine deiminase
  • pegylated recombinant human arginase
  • pegylated recombinant human arginase 1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06582524Phase 3Aug 30, 2024Immedica Pharma AB
NCT06085729Phase 1/Phase 2 (Phase 2)Mar 1, 2024University of Texas at Houston
NCT05829239Phase 2Jan 31, 2024Polaris Pharmaceuticals, Inc., Washington University in St. Louis
NCT05813327Phase 1/Phase 2 (Phase 2)Jan 31, 2024Polaris Group, Washington University in St. Louis
NCT06034977Phase 2Dec 1, 2023Chang Gung University
NCT05842512Phase 2Nov 30, 2023Polaris Group
NCT05712694Phase 3Nov 29, 2023Polaris Group
NCT06006286Phase 1/Phase 2 (Phase 2)Aug 8, 2023University of Texas at Houston
NCT05676853Phase 3Apr 4, 2023Aeglea Biotherapeutics
NCT05616624Phase 1/Phase 2 (Phase 2)Jan 31, 2023Polaris Group, Washington University in St. Louis
NCT05317819Phase 3Mar 14, 2022Polaris Group
NCT04965714Phase 2Dec 1, 2021University of Texas at Houston
NCT05001828Phase 1Aug 31, 2021Polaris Group
NCT04587830Phase 1Jun 16, 2020Chang Gung University, Polaris Group
NCT04136834Phase 1Nov 15, 2019Athenex, Inc.
NCT03922880Phase 1Apr 16, 2019Memorial Sloan-Kettering Cancer Center
NCT03921541Phase 3Apr 10, 2019Aeglea Biotherapeutics
NCT03455140Phase 1/Phase 2 (Phase 2)Jun 30, 2018University of Birmingham
NCT03498222Phase 1Jun 1, 2018Polaris Group, Roche, University of London
NCT03449901Phase 2May 9, 2018Polaris Pharmaceuticals, Inc., Washington University in St. Louis
Showing 20 of 51 trials
Page 1 / 3

Organizations

Research & Development (31)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Polaris GroupFor profit242032011
Bio-Cancer Treatment International LimitedFor profit7722008
The University of Hong KongAcademic/Hospital6022008
University of Texas at HoustonAcademic/Hospital6322011
Aeglea BiotherapeuticsFor profit5522016
Cornell UniversityAcademic/Hospital5022007
Washington University in St. LouisAcademic/Hospital4412018
Chang Gung UniversityAcademic/Hospital3122011
Chinese University of Hong KongAcademic/Hospital3022008
University of LondonAcademic/Hospital3122011
Barts & The London NHS TrustAcademic/Hospital2112011
Food and Drug AdministrationGovernment2222001
Ludwig Institute for Cancer ResearchAcademic/Hospital2212007
National Taiwan UniversityAcademic/Hospital2012011
Polaris Pharmaceuticals, Inc.For profit2012018
Athenex, Inc.For profit1112019
Austin HealthAcademic/Hospital1012011
California Cancer AssociatesAcademic/Hospital1012014
Cancer Research UKAcademic/Hospital1012011
Duke UniversityAcademic/Hospital1012011
31 organizations
Page 1 / 2